Clinical Consultations™: Understanding the Need for Proper Recognition and Management of Iron Deficiency Anemia in Patients with IBD

Released On
November 12, 2020

Expires On
November 12, 2021

Media Type
Internet

Completion Time
90 minutes

Specialty
Gastroenterology

Topic(s)
IBD

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

This activity is supported by an educational grant from American Regent.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)
  • Nurses — 1.5 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This online educational activity is directed towards gastroenterologists, primary care providers, obstetricians/gynecologists, hematologists, physicians, nurse practitioners, physician assistants, and nurses. Additional health care clinicians involved in the management of IDA in patients with IBD will also be invited to participate.

Program Overview

This online educational activity is designed to provide expert interpretation of current and emerging data on the diagnosis and treatment of iron deficiency anemia (IDA) in patients with inflammatory bowel disease (IBD). New guideline recommendations, diagnostic considerations, and therapeutic options are presented in a series of videos featuring 2 expert physicians conversing about the nuances of IDA/IBD and various clinical scenarios.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss the pathophysiology, etiology, and burden of IDA in patients with concomitant IBD
  • Review screening criteria, diagnosis, and therapeutic interventions for optimal management of IDA in patients with concomitant IBD
  • Analyze current data regarding efficacy, safety, administration routes, and clinical suitability to select individualized treatment strategies for optimal management of IDA in patients with concomitant IBD

Faculty

Gary R. Lichtenstein, MD

Gary R. Lichtenstein, MD

Professor of Medicine
Director, Center for Inflammatory Bowel Diseases
The Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania
Hospital of the University of Pennsylvania
Gastroenterology Division, Department of Internal Medicine
Perelman Center for Advanced Medicine
Philadelphia, PA

Stephen B. Hanauer, MD

Stephen B. Hanauer, MD

Professor of Medicine
Medical Director of Digestive Health Center
Chicago, IL

Accreditation Statement

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Disclosures of Conflicts of Interest

In accordance with ACCME guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Gary R. Lichtenstein, MD

  • Grant/Research Support: Celgene, Janssen Orthobiotech, Pfizer Pharmaceuticals, Takeda
  • Consultant: Abbvie, CellCeutrix, Celgene, Endo Pharmaceuticals, Ferring, Gilead, Janssen Orthobiotech, Eli Lilly, Merck, Morphic Therapeutics, Pfizer Pharmaceuticals, Prometheus Laboratories, Inc., Romark, Salix Pharmaceuticals / Valeant, Shire Pharmaceuticals, Takeda, UCB

Stephen B. Hanauer, MD

  • Consultant: AbbVie, Allergan, Amgen, Arena,Boehringer lngelheim, Bristol Myers Squibb, Celgene, Celtrion, Genentech, Gilead, GSK, Janssen, Lilly,, Merck, Nestle, Novartis, Pfizer, Progenity, Prometheus, Receptos, Salix, Samsung Bioepis, SeresTherapeutics, Takeda, Tigencx, UCB Pharma, VHsquared
  • Speaker's Bureau: AbbVie, Janssen, Pfizer, Takeda, American Regent.

The staff of Physicians’ Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Complete the activity (including pre- and postactivity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.